Abstract
This research examines the impact of the U.S. FDA's Regenerative Medicine Advanced Therapy (RMAT) designation on biotechnology and small pharmaceutical companies, focusing on both stock price reactions and drug development timelines. The research employs an event-study methodology to analyze share price movements following RMAT announcements and evaluates the long-term product development outcomes for these companies. Findings reveal that while RMAT designation leads to an initial short-term stock price increase of approximately 8.11% within five days, this optimism diminishes over time, with long-term trends showing a decline in stock value. Furthermore, products under RMAT designation exhibited longer development timelines compared to non-RMAT therapies, raising questions about the designation's effectiveness in accelerating product availability. The study underscores the complex implications of RMAT for stakeholders, emphasizing the need for strategic planning and further regulatory refinement to better align short-term investor expectations with long-term product development realities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
